FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered a pharmaceutical combination for treating a proliferative disease containing a) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-phenyl]benzamide (nilotinib) and b) at least one mTOR kinase inhibitor selected from a group including rapamycin RAD (sirolimus) and its derivatives/analogues, such as everolimus, or RAD001, CCI-779, ABT578, SAR543, ascomycin (ethyl analogue FK506), AP23573 and AP23841, an appropriate method of treating or preventing a proliferative disease, a method of treating leucosis with using such combination, as well as application thereof for treating or preventing a proliferative disease (versions). Synergetic action of the combination in treating cancer is shown. A mechanism of action of the combination is suggested: Bcr-Abl, , or Fit-3 kinase expression inhibition.
EFFECT: preparing the pharmaceutical combination for treating a proliferative disease.
7 cl
